应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
BNTX BioNTech SE
交易中 09-20 12:11:55 EDT
112.71
+0.20
+0.18%
最高
114.33
最低
111.20
成交量
48.11万
今开
111.43
昨收
112.51
日振幅
2.78%
总市值
267.99亿
流通市值
98.03亿
总股本
2.38亿
成交额
5,441万
换手率
0.55%
流通股本
8,697万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
制药公司BioNTech SE(BNTX.O)宣布IO102-IO103一线治疗晚期头颈癌的II期试验取得积极结果。
美港电讯 · 09-14
制药公司BioNTech SE(BNTX.O)宣布IO102-IO103一线治疗晚期头颈癌的II期试验取得积极结果。
美国食品药品监督管理局(FDA)批准了诺瓦瓦克斯医药(NVAX.O)更新的COVID-19疫苗。诺瓦瓦克斯医药(NVAX.
美港电讯 · 08-31
美国食品药品监督管理局(FDA)批准了诺瓦瓦克斯医药(NVAX.O)更新的COVID-19疫苗。诺瓦瓦克斯医药(NVAX.
扎克伯格称拜登政府迫使 Meta 审查 COVID-19 内容
Reuters · 08-27
扎克伯格称拜登政府迫使 Meta 审查 COVID-19 内容
美国将在全国范围内提供免费 COVID 检测,并启动宣传活动
Reuters · 08-24
美国将在全国范围内提供免费 COVID 检测,并启动宣传活动
异动解读 | FDA将批准新一代新冠疫苗,BioNTech SE股价拉升
异动解读 · 08-19
异动解读 | FDA将批准新一代新冠疫苗,BioNTech SE股价拉升
Biontech Se盘中异动 快速上涨5.05%报89.49美元
自选股智能写手 · 08-19
Biontech Se盘中异动 快速上涨5.05%报89.49美元
新冠疫苗概念盘前普遍扬升 诺瓦瓦克斯医药(NVAX)升逾1% 美FDA最早于本周批准更新版新冠疫苗
金吾财讯 · 08-19
新冠疫苗概念盘前普遍扬升 诺瓦瓦克斯医药(NVAX)升逾1% 美FDA最早于本周批准更新版新冠疫苗
辉瑞(PFE.US)、BioNTech(BNTX.US)流感mRNA疫苗积极结果公布
智通财经 · 08-17
辉瑞(PFE.US)、BioNTech(BNTX.US)流感mRNA疫苗积极结果公布
异动解读 | BioNTech股价大跌5.42% 新冠联合疫苗临床试验未达预期
异动解读 · 08-16
异动解读 | BioNTech股价大跌5.42% 新冠联合疫苗临床试验未达预期
Biontech Se盘中异动 大幅下跌5.04%
自选股智能写手 · 08-16
Biontech Se盘中异动 大幅下跌5.04%
辉瑞与BioNTech新研联合疫苗最新临床试验未达预期
老虎资讯综合 · 08-16
辉瑞与BioNTech新研联合疫苗最新临床试验未达预期
Biontech Se2024财年第二财季实现净利润-8.70亿美元,同比减少320.29%
自选股智能写手 · 08-12
Biontech Se2024财年第二财季实现净利润-8.70亿美元,同比减少320.29%
诺瓦瓦克斯医药(NVAX)跌1.96% 二季度总营收低于预期 公司COVID-19疫苗销量低于预期
金吾财讯 · 08-08
诺瓦瓦克斯医药(NVAX)跌1.96% 二季度总营收低于预期 公司COVID-19疫苗销量低于预期
BioNTech SE: TD Cowen将目标价从98美元下调至85美元。
智通财经 · 08-06
BioNTech SE: TD Cowen将目标价从98美元下调至85美元。
【分析:随着VIX达到自COVID-19市场恐慌以来的最高水平,加密市场或面临更大波动】金色财经报道,Abra场外期权交易主管Bohan Jiang表示,近期宏观经济低迷令衍生品市场措手不及,芝加哥期权交易所的波动率指数(VIX)飙升。
金色财经 · 08-06
【分析:随着VIX达到自COVID-19市场恐慌以来的最高水平,加密市场或面临更大波动】金色财经报道,Abra场外期权交易主管Bohan Jiang表示,近期宏观经济低迷令衍生品市场措手不及,芝加哥期权交易所的波动率指数(VIX)飙升。
异动解读 | BioNTech二季度营收低于预期 净亏损大增 股价盘前大跌
异动解读 · 08-05
异动解读 | BioNTech二季度营收低于预期 净亏损大增 股价盘前大跌
BioNtech(BNTX)盘前跌3.66% 二季度营收未达预期
金吾财讯 · 08-05
BioNtech(BNTX)盘前跌3.66% 二季度营收未达预期
更新版 1-转向抗癌药物,BioNTech 第二季度亏损翻了两番
Reuters · 08-05
更新版 1-转向抗癌药物,BioNTech 第二季度亏损翻了两番
BioNTech二季度营收低于预期,净亏损同比大增
老虎资讯综合 · 08-05
BioNTech二季度营收低于预期,净亏损同比大增
BioNTech SE(BNTX.O):2024年第二季度营收1.287亿欧元,市场预计1.316亿欧元。
汇通网 · 08-05
BioNTech SE(BNTX.O):2024年第二季度营收1.287亿欧元,市场预计1.316亿欧元。
公司概况
公司名称:
BioNTech SE
所属市场:
NASDAQ
上市日期:
--
主营业务:
BioNTech SE成立于2008年6月2日。该公司结合了数十年的免疫学,尖端治疗平台以及各种患者分析和生物信息学工具的开创性研究,开发针对癌症和其他疾病的个体化免疫疗法。该公司利用强大的新治疗机制,利用各种生物学靶点,利用每位患者免疫系统的力量,解决每位患者潜在疾病的独特分子特征。
发行价格:
--
{"stockData":{"symbol":"BNTX","market":"US","secType":"STK","nameCN":"BioNTech SE","latestPrice":112.71,"timestamp":1726848714426,"preClose":112.51,"halted":0,"volume":481083,"delay":0,"floatShares":86973795,"shares":237766235,"eps":-2.255516,"marketStatus":"交易中","marketStatusCode":2,"change":0.2,"latestTime":"09-20 12:11:55 EDT","open":111.43,"high":114.33,"low":111.2,"amount":54414788.18202,"amplitude":0.02782,"askPrice":112.7,"askSize":275,"bidPrice":112.45,"bidSize":81,"shortable":3,"etf":0,"ttmEps":-2.255516,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1726862400000},"adr":0,"listingDate":1570680000000,"adjPreClose":112.51,"adrRate":1,"preHourTrading":{"tag":"盘前","latestPrice":111.42,"preClose":112.51,"latestTime":"09:29 EDT","volume":8417,"amount":949395.93585,"timestamp":1726838974333},"postHourTrading":{"tag":"盘后","latestPrice":112.3,"preClose":112.51,"latestTime":"19:59 EDT","volume":158767,"amount":17862956.0501,"timestamp":1726790384765},"volumeRatio":0.347837,"impliedVol":0.4374,"impliedVolPercentile":0.8532},"requestUrl":"/m/hq/s/BNTX/wiki","defaultTab":"wiki","newsList":[{"id":"2467065343","title":"制药公司BioNTech SE(BNTX.O)宣布IO102-IO103一线治疗晚期头颈癌的II期试验取得积极结果。","url":"https://stock-news.laohu8.com/highlight/detail?id=2467065343","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467065343?lang=zh_cn&edition=full","pubTime":"2024-09-14 14:33","pubTimestamp":1726295624,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1574","BK4568","BK1191","BK4585","BK4588","BNTX","BK4551","BK4535","BK4139","01477","BK4548"],"gpt_icon":0},{"id":"2463679881","title":"美国食品药品监督管理局(FDA)批准了诺瓦瓦克斯医药(NVAX.O)更新的COVID-19疫苗。诺瓦瓦克斯医药(NVAX.","url":"https://stock-news.laohu8.com/highlight/detail?id=2463679881","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463679881?lang=zh_cn&edition=full","pubTime":"2024-08-31 02:31","pubTimestamp":1725042696,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK4588","BK4535","BK4139","NVAX","BK4585","BNTX","BK4568","159646","BK4551","BK4547","BK4548"],"gpt_icon":0},{"id":"2462131915","title":"扎克伯格称拜登政府迫使 Meta 审查 COVID-19 内容","url":"https://stock-news.laohu8.com/highlight/detail?id=2462131915","media":"Reuters","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462131915?lang=zh_cn&edition=full","pubTime":"2024-08-27 15:40","pubTimestamp":1724744421,"startTime":"0","endTime":"0","summary":" 路透8月27日 - Meta Platforms 首席执行官马克-扎克伯格说,拜登政府的高级官员曾向他的社交媒体公司施压,要求其在大流行病期间审查 COVID-19 的内容。该委员会在其 Facebook 帖子中称这封信是 \"言论自由的重大胜利\",并称扎克伯格承认 \"Facebook 审查了美国人\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKDWB100.SGD","LU0154236417.USD","LU0203347892.USD","LU0082616367.USD","BK4535","LU0070302665.USD","LU0056508442.USD","GB00B4LPDJ14.GBP","IE00BMPRXN33.USD","IE00BMPRXQ63.HKD","BK4588","IE00BFSS8Q28.SGD","LU0208291251.USD","IE00BN29S564.USD","IE0034235303.USD","BK4139","IE00BK4W5L77.USD","LU0106261372.USD","LU0130102774.USD","LU0170899867.USD","IE0005OL40V9.USD","IE00BK4W5M84.HKD","IE00B1XK9C88.USD","IE00BJJMRY28.SGD","LU0198837287.USD","IE00B4JS1V06.HKD","IE00BMPRXR70.SGD","IE0002270589.USD","LU0053666078.USD","LU0061475181.USD","LU0109391861.USD","LU0068578508.USD","BK4524","IE00BFSS7M15.SGD","META","BK4548","IE00BWXC8680.SGD","BK4592","IE00B19Z3581.USD","IE0009356076.USD","IE0004445239.USD","IE00B19Z3B42.SGD","IE00B19Z8W00.USD","GB00B4QBRK32.GBP","IE00B19Z9505.USD","IE00B1BXHZ80.USD","LU0006306889.USD","BNTX","IE00B7KXQ091.USD","IE00B7SZLL34.SGD"],"gpt_icon":1},{"id":"2461514382","title":"美国将在全国范围内提供免费 COVID 检测,并启动宣传活动","url":"https://stock-news.laohu8.com/highlight/detail?id=2461514382","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461514382?lang=zh_cn&edition=full","pubTime":"2024-08-24 00:01","pubTimestamp":1724428903,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) 路透8月23日 - 美国卫生官员周五表示,政府的COVID-19免费检测交付项目将于9月下旬重新开放,以赶上假日季节,他们还发起了一场针对有严重疾病风险人群的教育活动。 在过去三个月中,美国的 COVID 住院率和死亡率都有所上升。与 COVID-19 相关的住院率从 5 月初的每 10 万人 1.1 例跃升至 8 月初的 4.4 例。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BK4548","BK4588","BK4585","BK4535","BK4139","BNTX","BK4568"],"gpt_icon":0},{"id":"1168945164","title":"异动解读 | FDA将批准新一代新冠疫苗,BioNTech SE股价拉升","url":"https://stock-news.laohu8.com/highlight/detail?id=1168945164","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168945164?lang=zh_cn&edition=full","pubTime":"2024-08-19 23:18","pubTimestamp":1724080701,"startTime":"0","endTime":"0","summary":"新冠疫苗公司BioNTech SE盘中股价大涨5.22%,引起市场广泛关注。此前有消息称,美国食品和药物管理局将于本周最早批准新一代新冠疫苗。一旦获批,公司当前的新冠疫苗产品将被取代,其他新冠疫苗公司也会推出更新版本。这意味着大量新一代新冠疫苗需求将很快释放,BioNTech SE有望随之获益。尽管如此,机构分析师对BioNTech SE的盈利前景并不看好。这表明公司股价涨势存在一定限制。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTX"],"gpt_icon":0},{"id":"2460053201","title":"Biontech Se盘中异动 快速上涨5.05%报89.49美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2460053201","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460053201?lang=zh_cn&edition=full","pubTime":"2024-08-19 23:00","pubTimestamp":1724079658,"startTime":"0","endTime":"0","summary":"北京时间2024年08月19日23时00分,Biontech Se股票出现波动,股价急速拉升5.05%。截至发稿,该股报89.49美元/股,成交量40.4173万股,换手率0.17%,振幅4.63%。Biontech Se股票所在的生物技术行业中,整体涨幅为1.43%。Biontech Se公司简介:BioNTech 是一家总部位于德国的生物技术公司,专注于开发癌症疗法,包括个体化免疫疗法,以及包括新冠病毒在内的传染病疫苗。BioNTech 与多家大型制药公司合作,包括罗氏、礼来、辉瑞、赛诺菲和 Genmab。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081923005998e35613&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081923005998e35613&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4535","ALZN","BK4588","BK4585","BNTX","BK4139","BK4548","BK4568","BK4539","BK4551"],"gpt_icon":0},{"id":"2460083987","title":"新冠疫苗概念盘前普遍扬升 诺瓦瓦克斯医药(NVAX)升逾1% 美FDA最早于本周批准更新版新冠疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=2460083987","media":"金吾财讯","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460083987?lang=zh_cn&edition=full","pubTime":"2024-08-19 17:28","pubTimestamp":1724059684,"startTime":"0","endTime":"0","summary":"金吾财讯 | 新冠疫苗概念盘前普遍扬升,诺瓦瓦克斯医药 涨1.23%,Moderna涨1.15%,BioNTech涨0.67%,辉瑞涨0.39%。据悉美国食品药品监督管理局正准备最早于本周批准一批针对当前流行病毒株的更新版新冠疫苗。此前美国疾病控制与预防中心建议6个月及以上年龄的人群接种最新的新冠疫苗以及流感疫苗。辉瑞和Moderna已经准备好充足的新冠疫苗库存,一旦获得官方批准,预计可以在几天内开始分发。相比之下,诺瓦瓦克斯医药的新冠疫苗采用蛋白质技术,生产周期较长。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210810/MzE4MDg0MTAxNw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MzE4MDg0MTAxNw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"279034","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999011175.SGD","LU0306806265.USD","IE00BBT3K403.USD","159646","LU0225771236.USD","LU0058720904.USD","BK4535","BK4550","BK4568","PFE","SG9999003800.SGD","BK4547","LU1883839398.USD","LU1894683264.USD","LU0289739699.SGD","LU1023059063.AUD","BK4501","IE00BLSP4452.SGD","SGXZ57979304.SGD","BK4532","MRNA","NVAX","LU0170899867.USD","LU0234572021.USD","BK4551","IE0002270589.USD","LU1894683348.USD","BK4139","BNTX","IE00B19Z3581.USD","LU0985481810.HKD","SG9999002232.USD","LU0225284248.USD","BK4585","LU0321505439.SGD","SG9999001176.USD","SG9999013999.USD","BK4588","BK4533","BK4548","SG9999002224.SGD","LU0321505868.SGD","LU0868494617.USD","LU0306807586.USD","LU1066053197.SGD","BK4581","BK4534","IE00BLSP4239.USD","BK4592","LU1057294990.SGD"],"gpt_icon":1},{"id":"2460275973","title":"辉瑞(PFE.US)、BioNTech(BNTX.US)流感mRNA疫苗积极结果公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2460275973","media":"智通财经","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460275973?lang=zh_cn&edition=full","pubTime":"2024-08-17 07:38","pubTimestamp":1723851532,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,今日,辉瑞和BioNTech公布其第二代三价流感mRNA疫苗2期试验的最新进展,该试验显示了令人鼓舞的数据,与标准流感疫苗相比,该疫苗对所有病毒株均显示具有强大的免疫原性。mRNA技术的灵活性及其快速制造能力可能在未来几年内实现更好的病毒株匹配,并且在流感大流行的情况下,mRNA技术可以实现快速、大规模的疫苗生产。目前为止,未报告任何关于该疫苗的安全信号。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1165840.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B19Z3581.USD","SG9999003800.SGD","IE00BLSP4452.SGD","BK4139","BK4588","BK4535","BK4533","BK4534","LU0225284248.USD","LU0456855351.SGD","SG9999002224.SGD","BK4550","SG9999011175.SGD","LU1066053197.SGD","BNTX","LU0289739699.SGD","BK4581","LU1066051498.USD","SG9999001176.SGD","159646","IE00BBT3K403.USD","LU0058720904.USD","BK4568","BK4585","IE00B19Z3B42.SGD","BK4551","LU0321505868.SGD","LU0985481810.HKD","LU0306807586.USD","BK4548","SGXZ57979304.SGD","LU0321505439.SGD","LU0306806265.USD","SG9999001176.USD","IE0002270589.USD","LU0234572021.USD","LU0225771236.USD","LU1883839398.USD","LU0170899867.USD","LU0122379950.USD","SG9999002232.USD","IE00BLSP4239.USD","BK4007","BK4592","LU1057294990.SGD","LU0868494617.USD","SG9999013999.USD","LU1023059063.AUD","PFE","LU1894683348.USD"],"gpt_icon":1},{"id":"1156043884","title":"异动解读 | BioNTech股价大跌5.42% 新冠联合疫苗临床试验未达预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1156043884","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156043884?lang=zh_cn&edition=full","pubTime":"2024-08-16 22:34","pubTimestamp":1723818862,"startTime":"0","endTime":"0","summary":"德国生物技术公司BioNTech SE今日盘中股价大跌5.42%,引发市场广泛关注。这一下跌与该公司与辉瑞合作研发的新冠病毒和流感联合疫苗临床试验未达预期目标有关。\n\n据悉,辉瑞和BioNTech针对18至64岁人群的mRNA基础流感与新冠病毒联合疫苗项目第三阶段临床试验未能达到主要目标。辉瑞公司表示将继续评估流感疫苗项目。\n\n分析人士指出,由于该联合疫苗项目未能取得预期进展,市场对BioNTech未来发展前景产生了担忧,从而引发了股价下跌。作为新冠疫苗的主要研发商之一,BioNTech在疫苗研发领域的表现备受关注。此次临床试验未果,无疑给公司的发展蒙上了一层阴影。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTX"],"gpt_icon":0},{"id":"2459439392","title":"Biontech Se盘中异动 大幅下跌5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2459439392","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459439392?lang=zh_cn&edition=full","pubTime":"2024-08-16 22:31","pubTimestamp":1723818666,"startTime":"0","endTime":"0","summary":"北京时间2024年08月16日22时31分,Biontech Se股票出现波动,股价大幅下跌5.04%。Biontech Se股票所在的生物技术行业中,整体跌幅为0.23%。Biontech Se公司简介:BioNTech 是一家总部位于德国的生物技术公司,专注于开发癌症疗法,包括个体化免疫疗法,以及包括新冠病毒在内的传染病疫苗。BioNTech 与多家大型制药公司合作,包括罗氏、礼来、辉瑞、赛诺菲和 Genmab。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081622310798e352fd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081622310798e352fd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4588","BNTX","BK4548","BK4535","BK4007","CING","BK4568","BK4585","BK4551"],"gpt_icon":1},{"id":"1149164305","title":"辉瑞与BioNTech新研联合疫苗最新临床试验未达预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1149164305","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149164305?lang=zh_cn&edition=full","pubTime":"2024-08-16 18:57","pubTimestamp":1723805871,"startTime":"0","endTime":"0","summary":"8月16日,$辉瑞(PFE)$与BioNTech就针对18至64岁人群的mRNA基础流感与新冠病毒联合疫苗项目提供最新进展。该疫苗第三阶段临床试验未能达到主要目标。辉瑞公司将继续评估流感疫苗项目。受此消息影响,BioNTech美股盘前跌近3%。","market":"us","thumbnail":"https://static.tigerbbs.com/5ce7e4c84e3c54b81fbaee9cb1c77ad9","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5ce7e4c84e3c54b81fbaee9cb1c77ad9"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"BioNTech新疫苗第三阶段临床试验未达预期","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTX","PFE"],"gpt_icon":0},{"id":"2458978586","title":"Biontech Se2024财年第二财季实现净利润-8.70亿美元,同比减少320.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2458978586","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458978586?lang=zh_cn&edition=full","pubTime":"2024-08-12 00:06","pubTimestamp":1723392379,"startTime":"0","endTime":"0","summary":"8月12日,Biontech Se公布财报,公告显示公司2024财年第二财季净利润为-8.70亿美元,同比减少320.29%;其中营业收入为1.39亿美元,同比减少24.04%,每股基本收益为-3.66美元。从资产负债表来看,Biontech Se总负债33.93亿美元,其中短期债务37.83百万美元,资产负债比为7.03,流动比率为7.54。机构评级:截至2024年8月12日,当前有17家机构对Biontech Se目标价做出预测,其中目标均价为111.65美元,其中最低目标价为84.52美元,最高目标价为170.03美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081200062695903f7b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081200062695903f7b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BNTX"],"gpt_icon":0},{"id":"2457143493","title":"诺瓦瓦克斯医药(NVAX)跌1.96% 二季度总营收低于预期 公司COVID-19疫苗销量低于预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2457143493","media":"金吾财讯","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457143493?lang=zh_cn&edition=full","pubTime":"2024-08-08 22:00","pubTimestamp":1723125633,"startTime":"0","endTime":"0","summary":"金吾财讯 | 诺瓦瓦克斯医药(NVAX)股价走低,截至发稿,跌1.96%,报10.5美元,成交额4383.46万美元。公司周四公布第二季度收入低于分析师预期,原因是其 COVID-19 疫苗销量低于预期。伦敦证券交易所的数据显示,该公司第二季度的总营收为 4.155 亿美元,低于分析师平均预期的 4.586 亿美元。","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/ZjBiNzEwNDA3MTQ3NjM4OTQ3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZjBiNzEwNDA3MTQ3NjM4OTQ3.jpg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"278726","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159646","BNTX","NVAX"],"gpt_icon":1},{"id":"2457064268","title":"BioNTech SE: TD Cowen将目标价从98美元下调至85美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2457064268","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457064268?lang=zh_cn&edition=full","pubTime":"2024-08-06 14:24","pubTimestamp":1722925480,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4551","BK4566","BK4535","BK4585","BK4588","TD","BK4548","BK4207","BK4139","BK4568","BNTX"],"gpt_icon":0},{"id":"2457082847","title":"【分析:随着VIX达到自COVID-19市场恐慌以来的最高水平,加密市场或面临更大波动】金色财经报道,Abra场外期权交易主管Bohan Jiang表示,近期宏观经济低迷令衍生品市场措手不及,芝加哥期权交易所的波动率指数(VIX)飙升。","url":"https://stock-news.laohu8.com/highlight/detail?id=2457082847","media":"金色财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457082847?lang=zh_cn&edition=full","pubTime":"2024-08-06 06:29","pubTimestamp":1722896945,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"'https://api.jinse.com/noah/v2/lives","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinse_live","symbols":["HODL","BITO","BK4532","BRRR","BK4551","BK4139","UVXY","BK4588","TVIX","BK4112","VIXY","DEFI","SVXY","BK4594","FBTC","BNTX","CBOE","BK4585","VXX","BTCW","BK4548","GBTC","VIXmain","BK4535","BTCO","EZBC","IBIT","VBTC.AU","BK4568"],"gpt_icon":0},{"id":"1135212246","title":"异动解读 | BioNTech二季度营收低于预期 净亏损大增 股价盘前大跌","url":"https://stock-news.laohu8.com/highlight/detail?id=1135212246","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135212246?lang=zh_cn&edition=full","pubTime":"2024-08-05 22:13","pubTimestamp":1722867234,"startTime":"0","endTime":"0","summary":"德国生物技术公司BioNTech SE今日盘前股价大跌5.68%,引发市场广泛关注。公司今日公布的2024年第二季度财报显示,营收仅为1.287亿欧元,低于市场预期的1.316亿欧元。同时,公司第二季度净亏损高达8.078亿欧元,同比去年同期的1.904亿欧元大幅增加。面对疫苗业务的放缓,BioNTech正在转型,将战略重点转向新的癌症治疗领域。BioNTech维持了2024年全年收入在25亿至31亿欧元的预期,但大部分收入预计将集中在年底。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTX"],"gpt_icon":0},{"id":"2457740260","title":"BioNtech(BNTX)盘前跌3.66% 二季度营收未达预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2457740260","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457740260?lang=zh_cn&edition=full","pubTime":"2024-08-05 18:51","pubTimestamp":1722855084,"startTime":"0","endTime":"0","summary":"金吾财讯 | BioNtech(BNTX)盘前股价走低,暂跌3.66%,报79.01美元。公司2024年第二季度营收1.287亿欧元,市场预计1.316亿欧元,未达预期,公司COVID-19疫苗销售持续下滑。","market":"other","thumbnail":"https://static.szfiu.com/news/20210625/OGIwZDQyMDYwMGIwOWQ1NTkxMDE1Mzc1NTA2MDQ=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/OGIwZDQyMDYwMGIwOWQ1NTkxMDE1Mzc1NTA2MDQ=.jpg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"278563","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTX"],"gpt_icon":0},{"id":"2457372742","title":"更新版 1-转向抗癌药物,BioNTech 第二季度亏损翻了两番","url":"https://stock-news.laohu8.com/highlight/detail?id=2457372742","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457372742?lang=zh_cn&edition=full","pubTime":"2024-08-05 18:14","pubTimestamp":1722852840,"startTime":"0","endTime":"0","summary":" 路透柏林8月5日 - 德国生物技术公司周一表示,在其 COVID-19 疫苗销售急剧下降之后,该公司将战略重点转向新的癌症治疗,因此第二季度亏损同比翻了两番。,去年同期亏损1.904亿美元。该公司与美国合作伙伴辉瑞公司 合作开发的COVID-19疫苗在大流行期间被广泛使用,使这家德国小型生物技术公司成为家喻户晓的品牌。BioNTech 确认了 2024 年的收入预期,即 25 亿欧元至 31 亿欧元,其中大部分收入预计将在年底产生。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0122379950.USD","BK4139","IE00BLSP4452.SGD","LU0321505439.SGD","LU1883839398.USD","BK4550","IE0002270589.USD","LU1066053197.SGD","SG9999002232.USD","BK4581","SG9999011175.SGD","BK4535","SGXZ57979304.SGD","LU1894683348.USD","IE00BBT3K403.USD","BNTX","LU1894683264.USD","BK4533","LU0058720904.USD","LU0289739699.SGD","LU0868494617.USD","SG9999001176.SGD","LU0234572021.USD","IE00B19Z3581.USD","SG9999003800.SGD","BK4548","LU0456855351.SGD","BK4551","SG9999002224.SGD","SG9999013999.USD","LU1057294990.SGD","BK4592","BK4007","BK4585","BK4588","LU0321505868.SGD","BK4534","LU0170899867.USD","IE00BLSP4239.USD","LU1023059063.AUD","SG9999001176.USD","LU1066051498.USD","BK4568","IE00B19Z3B42.SGD"],"gpt_icon":1},{"id":"1168772141","title":"BioNTech二季度营收低于预期,净亏损同比大增","url":"https://stock-news.laohu8.com/highlight/detail?id=1168772141","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168772141?lang=zh_cn&edition=full","pubTime":"2024-08-05 18:03","pubTimestamp":1722852186,"startTime":"0","endTime":"0","summary":"COVID-19 疫苗销量大幅下滑。","market":"us","thumbnail":"https://static.tigerbbs.com/66c0e8d7770eb427d336ff2dfdad8c9a","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/66c0e8d7770eb427d336ff2dfdad8c9a"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"BioNTech二季度营收1.287亿欧元,低于预期","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTX"],"gpt_icon":1},{"id":"2457744906","title":"BioNTech SE(BNTX.O):2024年第二季度营收1.287亿欧元,市场预计1.316亿欧元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2457744906","media":"汇通网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457744906?lang=zh_cn&edition=full","pubTime":"2024-08-05 18:02","pubTimestamp":1722852124,"startTime":"0","endTime":"0","summary":null,"market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://kx.fx678.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_huitong","symbols":["BNTX","BK4551","BK4548","EURmain","EUO","BK4568","BK4139","FXE","MEURmain","BK4588","BK4585","BK4535"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biontech.de","stockEarnings":[{"period":"1week","weight":0.0715},{"period":"1month","weight":0.2709},{"period":"3month","weight":0.3293},{"period":"6month","weight":0.2252},{"period":"1year","weight":0.0359},{"period":"ytd","weight":0.066}],"compareEarnings":[{"period":"1week","weight":0.0213},{"period":"1month","weight":0.022},{"period":"3month","weight":0.0486},{"period":"6month","weight":0.0955},{"period":"1year","weight":0.3017},{"period":"ytd","weight":0.2013}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"BioNTech SE成立于2008年6月2日。该公司结合了数十年的免疫学,尖端治疗平台以及各种患者分析和生物信息学工具的开创性研究,开发针对癌症和其他疾病的个体化免疫疗法。该公司利用强大的新治疗机制,利用各种生物学靶点,利用每位患者免疫系统的力量,解决每位患者潜在疾病的独特分子特征。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.036134},{"month":2,"riseRate":0.2,"avgChangeRate":-0.029347},{"month":3,"riseRate":0.8,"avgChangeRate":0.158218},{"month":4,"riseRate":0.2,"avgChangeRate":0.046183},{"month":5,"riseRate":0.8,"avgChangeRate":0.071246},{"month":6,"riseRate":0.6,"avgChangeRate":0.036711},{"month":7,"riseRate":1,"avgChangeRate":0.177192},{"month":8,"riseRate":0.6,"avgChangeRate":-0.048295},{"month":9,"riseRate":0.4,"avgChangeRate":0.013158},{"month":10,"riseRate":0.75,"avgChangeRate":0.033872},{"month":11,"riseRate":1,"avgChangeRate":0.26222},{"month":12,"riseRate":0.4,"avgChangeRate":-0.023804}],"exchange":"NASDAQ","name":"BioNTech SE","nameEN":"BioNTech SE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.27.0","shortVersion":"4.27.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BioNTech SE(BNTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供BioNTech SE(BNTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"BioNTech SE,BNTX,BioNTech SE股票,BioNTech SE股票老虎,BioNTech SE股票老虎国际,BioNTech SE行情,BioNTech SE股票行情,BioNTech SE股价,BioNTech SE股市,BioNTech SE股票价格,BioNTech SE股票交易,BioNTech SE股票购买,BioNTech SE股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BioNTech SE(BNTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供BioNTech SE(BNTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}